Ivermectin Interacts With Human ABCG2

Marton Jani, Ildiko Makai, Emese Kis, Pal Szabo, Tunde Nagy, Peter Krajcsi,
Anne Lespine

► To cite this version:

Marton Jani, Ildiko Makai, Emese Kis, Pal Szabo, Tunde Nagy, et al.. Ivermectin Interacts With Human ABCG2. Journal of Pharmaceutical Sciences, 2011, 100 (1), pp.94-97. 10.1002/jps.22262 . hal-02645949

HAL Id: hal-02645949

<https://hal.inrae.fr/hal-02645949>

Submitted on 29 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Ivermectin Interacts With Human ABCG2

MÁRTON JANI,¹ ILDIKÓ MAKAI,¹ EMESE KIS,¹ PÁL SZABÓ,² TÜNDE NAGY,¹ PÉTER KRAJCSI,¹ ANNE LESPINE³

¹Solvo Biotechnology, Budaörs, Hungary

²Chemical Research Centre, Hungarian Academy of Sciences, Budapest, Hungary

³INRA UR66, F-31027 Toulouse, France

Received 10 February 2010; accepted 10 May 2010

Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.22262

ABSTRACT: Ivermectin is an antiparasitic drug frequently administered to humans. It has a limited brain exposure that is attributed to the efflux activity of ABCB1/Abcb1. ABCG2/Abcg2 is also a major transporter present in most pharmacologically important barriers. However, interaction of ivermectin with Abcg2 shows species specificity and in many studies was confounded by the masking effect of ABCB1/Abcb1. In this study using cellular and membrane assays we show that ivermectin displays a high-affinity interaction with human ABCG2 with IC₅₀ values in the 1–1.5 μ M range. This interaction may have implications in human ABCG2-mediated drug–drug interactions of ivermectin. © 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci

Keywords: BCRP; macrocyclic lactones; ADME; toxicity; ABC transporter

INTRODUCTION

Ivermectin has long been considered a model substrate of ABCB1 (P-glycoprotein, MDR1). Ivermectin brain exposure increased 70-fold in CF-1 mice deficient in Abcb1a,¹ 87-fold in Abcb1a knockout mice² leading to a 100-fold increase in neurotoxicity.² Abcb1 is a crucial determinant of ivermectin pharmacokinetics inasmuch as several coadministered Abcb1-interacting drugs have been shown to significantly alter pharmacokinetics of ivermectin across a board of different species (reviewed in Refs. 3,4).

Ivermectin is used in veterinary medicine to treat gastrointestinal infections. It has also been approved for human use. It is mostly used in tropical countries for onchocerciasis but it is also used in most of the occidental countries to treat strongyloidiasis and scabies. Although it has been used to treat humans for more than 20 years, very little pharmacokinetics data was published. Nevertheless, it is known that ivermectin is metabolized essentially through CYP3A4 in the liver.⁵ The interaction with human ABC transporters such as ABCB1⁶ and multiple members of the ABCC subfamily⁷ has also been described and may contribute to the disposition of the drug in humans as it has been previously shown in mice.^{1,2,8} A clinical drug–drug interaction with

azithromycin yielding an estimated 1.37-fold increase in ivermectin bioavailability was also published.⁹ As azithromycin, an ABCB1 substrate does not interact with CYP3A4; it was suggested that this drug–drug interaction was ABCB1-mediated.⁹

ABCG2/Abcg2 (BCRP, MXR) is a broad substrate specificity transporter expressed in multiple pharmacologically and physiologically important barriers (reviewed in Ref.¹⁰). It affects pharmacokinetics of drugs in mice^{11–13} and in humans.^{14,15} Interaction of ivermectin with ABCG2/Abcg2 seems to display species specificity as it was shown to inhibit bovine ABCG2¹⁶ but not the mouse ortholog.¹⁷ No interaction was seen *in vivo* in Abcg2 knockout versus wild-type mice comparison either.¹⁸ Albeit, the *in vivo* data were generated on an Abcb1a,b background.

In this study utilizing multiple *in vitro* methods we are showing that ivermectin interacts with human ABCG2 with high affinity.

MATERIALS AND METHODS

Chemicals

Ko134 and Ko143 was from Solvo Biotechnology (Budaörs, Hungary). GF120918 was a kind gift from Prof. Ferenc Fülöp (University of Szeged, Hungary). All other chemicals were from Sigma (Hungary, Budapest).

Cell Lines

PLB985-BCRP¹⁹ and parental cells were kindly provided by Dr. Katalin Németh (National Blood

Correspondence to: Péter Krajcsi (Telephone: 36-23-503940; fax: 36-23-503941; E-mail: krajcsi@solvo.com)

Journal of Pharmaceutical Sciences

© 2010 Wiley-Liss, Inc. and the American Pharmacists Association

Transfusion Service, Hungary). Cells were maintained in Gibco's Advanced RPMI 1640 from Cseretex (Hungary, Budapest). All media were supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 µg/mL penicillin–streptomycin and were grown under standard conditions (5% CO₂, 37°C).

Vesicular Transport Assay

The vesicular transport assay was performed using the PREDIVEZ Kit (Solvo Biotechnology) for human ABCG2 (SB-ABCG2-HAM-PREDIVEZ™-VT kit) using estrone-3-sulfate (E3S) as probe substrate according to the manufacturer's recommendations.

For K_i determination ivermectin was set to final concentrations 50, 16.7, 5.56, 1.85, 0.617, 0.206, and 0.0686 µM, and its effect measured on E3S transport at 50, 16.7, 5.56 and 1.86 µM concentrations. Data were plotted in Dixon's representation and K_i was derived from the x -axis coordinates of the intersections of fitted linears.

Hoechst Assay

The Hoechst assay was performed as described earlier.¹⁹ Accumulation of Hoechst 33342 dye in PLB985-BCRP cells was measured in a fluorometer (Fluoroskan Ascent Type 374) at 350 nm (excitation) and 460 nm (emission). The fluorescence intensities were recorded for 15 min. The positive control measurements to determine 100% inhibition were carried out in the presence of 300 nM Ko134.

ATPase Activity

ATPase activity was measured as described previously.²⁰ The PREDEASY ATPase kit for ABCG2-HAM was from Solvo Biotechnology and was used according to the manufacturer's instructions.

Data Analysis

Experiments were carried out at least twice with data points measured with three parallels. In the case of ATPase and Hoechst assays relative inhibition was plotted with the 100% reference provided by 300 nM Ko134. For vesicular transport studies relative activity was plotted with vehicle control as 100% reference.

Sigmoidal dose–response curves were fitted onto effect versus log concentration plots with GraphPad PRISM 4.0 (GraphPad Software, Inc., La Jolla, CA) and IC₅₀ values derived from best-fit parameters.

RESULTS AND DISCUSSION

To test interaction of ivermectin with human ABCG2 inhibition experiments were carried out. In mammalian membrane vesicles specifically overexpressing

human ABCG2²¹ ivermectin inhibited E3S transport with an IC₅₀ of 1.5 µM (Fig. 1A). The drug inhibited ABCG2-mediated efflux of the Hoechst dye with a similar potency (IC₅₀ of 1 µM, Fig. 1B). The good correlation observed between IC₅₀ values measured in membrane as well as cellular systems (1.5 µM vs. 1 µM, respectively) indicates that ivermectin has a reasonable membrane permeability.²⁰ To get a preliminary indication on the nature of interaction, ivermectin was tested in an ATPase assay using membranes overexpressing the human protein. Interestingly, ivermectin inhibited the basal vanadate sensitive activity of ABCG2 with the same efficacy as Ko134, the reference inhibitor (Fig. 2). The lack of stimulation of the basal ABCG2 activity, however, does not necessarily indicate lack of transport as ivermectin inhibited the basal ATPase activity of ABCB1 in a similar fashion.⁷

The inhibitory potency of ivermectin is within the range of other known potent ABCG2 inhibitors

Figure 1. Ivermectin inhibits ABCG2 function in membrane vesicles and in cells. Ivermectin was incubated at final concentrations indicated with membrane vesicles (A) or cells (B) overexpressing human ABCG2. Transport of 3H-E3S (A) or Hoechst33342 (B) was measured and inhibition of transport is shown. Data points represent arithmetic means with standard deviations of three replicates.

Figure 2. Effect of ivermectin on ABCG2 ATPase. Membrane vesicles (20 μg/well) were incubated with indicated concentrations of ivermectin for 40 min at 32°C. The sodium orthovanadate sensitive activity was plotted. Data points represent arithmetic means with standard deviations of three replicates.

(Tab. 1). Ivermectin seems particularly potent in cellular assays.

In sum, ivermectin interacts with human ABCG2 with an affinity (Tab. 1; K_i of 1.4 μM, determined in vesicular transport assay, Fig. 3) close to the affinity (0.44 μM) observed for ABCB1.²² To elucidate the mechanism of the interaction transport experiments need to be performed in a relevant barrier model. *In vivo* investigations have to be carried out using ABCB1/Abcb1 and ABCG2/Abcg2 specific inhibitors or ABCG2/Abcg2 knockout animals generated on a ABCB1/Abcb1–/– background in a species where ivermectin interaction with ABCG2/Abcg2 can be demonstrated *in vitro*. Alternatively, ABCG2 and ABCB1 functions can specifically be knocked down using RNAi technology employing adenovirus or adeno-associated virus vectors.

In some humans ivermectin plasma levels may reach 100 nM⁹ that is about 10% of the IC₅₀ values measured *in vitro* (Tab. 1). Albeit this is the total plasma concentration of ivermectin it was shown that total plasma concentration of a drug yields better *in vitro*–*in vivo* correlations than using the unbound plasma concentration when calculations are based on

Table 1. Comparison of Observed IC₅₀ Values of ABCG2 Inhibitors in *In Vitro* Assays

	Vesicular Transport	ATPase Inhibition	Hoechst Efflux Inhibition
Ivermectin	1.5	1.68	1.0
Ko134	0.069	0.011	0.22
GF120918	0.046	0.11	None detected
Sulfasalazine	0.21	None detected	None detected
Novobiocin	0.11	22	19

Values are given in μM.

Figure 3. Inhibition of BCRP-mediated E3S transport by ivermectin in Dixon's representation. Linear portion of ivermectin series is shown. E3S concentrations were 50, 16.7, 5.56, and 1.85 μM. The intersections yield a K_i of 1.4 μM.

total concentration of the drug in the *in vitro* assay.^{23,24} Therefore, ivermectin is a potential perpetrator in drug–drug interactions in countries where it is licensed for human use. Nevertheless, clinical effect of this interaction on common substrates of ABCB1 and ABCG2 may be limited due to the masking effect of ABCB1.

ACKNOWLEDGMENTS

The work was supported by Hungarian grant Asboth-XTTPSRT1 and European Community grants Biosim-2004-005137; Liintop-LSHB-CT-2006-037499; and Memtrans-LSHB-CT-2006-518246.

REFERENCES

1. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR. 1999. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. *Drug Metab Dispos* 27:581–587.
2. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Riele HP, Berns AJ, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. *Cell* 77:491–502.
3. Lespine A, Dupuy J, Alvinerie M, Comera C, Nagy T, Krajcsi P, Orlowski S. 2009. Interaction of macrocyclic lactones with the multidrug transporters: The bases of the pharmacokinetics of lipid-like drugs. *Curr Drug Metab* 10:272–288.
4. Gonzalez-Canga A, Fernandez-Martinez N, Sahagun-Prieto A, Diez-Liebana MJ, Sierra-Vega M, Garcia-Vieitez JJ. 2009. A review of the pharmacological interactions of ivermectin in several animal species. *Curr Drug Metab* 10:359–368.

5. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW. 1998. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. *Xenobiotica* 28:313–321.
6. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the *mdr1a* P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. *J Clin Invest* 96:1698–1705.
7. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M. 2006. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). *Chem Biol Interact* 159: 169–179.
8. Kiki-Mvouaka S, Menez C, Borin C, Lyazrhi F, Foucaud-Vignault M, Dupuy J, Collet X, Alvinerie M, Lespine A. 2010. Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin and moxidectin in mice. *Drug Metab Dispos* 38:573–580.
9. El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. 2008. The effect of azithromycin on ivermectin pharmacokinetics—A population pharmacokinetic model analysis. *PLoS Negl Trop Dis* 2:e236.
10. Sarkadi B, Homolya L, Szakacs G, Varadi A. 2006. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. *Physiol Rev* 86: 1179–1236.
11. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. 2008. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. *Drug Metab Dispos* 36: 995–1002.
12. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. 2006. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. *Mol Pharm* 3:55–61.
13. Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH. 2009. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. *Clin Cancer Res* 15:3084–3093.
14. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB. 2008. Breast cancer resistance protein (ABCG2) and drug disposition: Intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. *Pharmacogenet Genomics* 18:439–448.
15. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y. 2008. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. *Clin Pharmacol Ther* 84:95–103.
16. Merino G, Real R, Baro MF, Gonzalez-Lobato L, Prieto JG, Alvarez AI, Marques MM. 2009. Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: Increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors. *Drug Metab Dispos* 37:5–9.
17. Muenster U, Grieshop B, Ickenroth K, Gnoth MJ. 2008. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug–drug interactions. *Pharm Res* 25:2320–2326.
18. Geyer J, Gavrilova O, Petzinger E. 2009. Brain penetration of ivermectin and selamectin in *mdr1a,b* P-glycoprotein- and *bcrp*-deficient knockout mice. *J Vet Pharmacol Ther* 32:87–96.
19. Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P. 2009. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: Implications for drug resistance. *Ann Rheum Dis* 68:1201–1207.
20. von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. 2009. A novel screening strategy to identify ABCB1 substrates and inhibitors. *Naunyn Schmiedeberg Arch Pharmacol* 379:11–26.
21. Glavinas H, Kis E, Pal A, Kovacs R, Jani M, Vagi E, Molnar E, Bansaghi S, Kele Z, Janaky T, Bathori G, von Richter O, Koomen GJ, Krajcsi P. 2007. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: A useful tool to detect drug–transporter interactions. *Drug Metab Dispos* 35:1533–1542.
22. Lespine A, Martin S, Dupuy J, Roulet A, Pineau T, Orlowski S, Alvinerie M. 2007. Interaction of macrocyclic lactones with P-glycoprotein: Structure–affinity relationship. *Eur J Pharm Sci* 30:84–94.
23. Margolis JM, Obach RS. 2003. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. *Drug Metab Dispos* 31:606–611.
24. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos* 27:1350–1359.